<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545127</url>
  </required_header>
  <id_info>
    <org_study_id>000050</org_study_id>
    <secondary_id>2014-000670-20</secondary_id>
    <nct_id>NCT02545127</nct_id>
  </id_info>
  <brief_title>Trial Exploring the Efficacy and Safety of FE 202767</brief_title>
  <acronym>Mermaid</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Multicentre Trial Exploring the Efficacy and Safety of Intra-nasal Administration of FE 202767 in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the safety and efficacy of FE 202767 compared to placebo in
      increasing milk production in subjects with preterm delivery and inadequate milk production.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of mother's own milk produced</measure>
    <time_frame>Over Days 1 to 14</time_frame>
    <description>The volume of mother's own milk produced for each treatment day is weighed and recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of maternal subjects who produce at least 500 mL of mother's own milk</measure>
    <time_frame>On Day 10</time_frame>
    <description>Milk volume is weighed and recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of maternal subjects who produce at least 750 mL of mother's own milk</measure>
    <time_frame>On Day 10</time_frame>
    <description>Milk volume is weighed and recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of mother's own milk produced</measure>
    <time_frame>On Day 17</time_frame>
    <description>Milk volume is weighed and recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of mother's own milk fed to the infant(s)</measure>
    <time_frame>Over Days 1 to 14</time_frame>
    <description>Milk volume is weighed and recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of formula/donor milk fed to the infant(s)</measure>
    <time_frame>Over Days 1 to 14</time_frame>
    <description>Milk volume is weighed and recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum-prolactin level before milk expression in the maternal subject</measure>
    <time_frame>From baseline to Day 3 (+2 days)</time_frame>
    <description>The exposure will be calculated based on the number of administrations and actual dosing times .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum-prolactin level before milk expression in the maternal subject</measure>
    <time_frame>From baseline to Day 10 (+2 days)</time_frame>
    <description>The exposure will be calculated based on the number of administrations and actual dosing times .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Merotocin concentration in milk produced</measure>
    <time_frame>On Day 3 (+2 days)</time_frame>
    <description>Concentration measured from sample of milk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Merotocin concentration in milk produced</measure>
    <time_frame>On Day 10 (+2 days)</time_frame>
    <description>Concentration measured from sample of milk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight in the infant(s)</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Measured as change in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in length in the infant(s)</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Measured as change in length</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in head circumference in the infant(s)</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Measured as change in circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum sodium (S-Na) in the infant(s)</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Measured as change in S-Na level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure of the maternal subject</measure>
    <time_frame>From baseline to Day 3 (+2 days)</time_frame>
    <description>Measured as change in sitting blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure of the maternal subject</measure>
    <time_frame>From baseline to Day 10 (+2 days)</time_frame>
    <description>Measured as change in sitting blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure of the maternal subject</measure>
    <time_frame>From baseline to Day 15 (+2 days)</time_frame>
    <description>Measured as change in sitting blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate of the maternal subject</measure>
    <time_frame>From baseline to Day 3 (+2 days)</time_frame>
    <description>Measured by using the equipment used at site for general practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate of the maternal subject</measure>
    <time_frame>From baseline to Day 10 (+2 days)</time_frame>
    <description>Measured by using the equipment used at site for general practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate of the maternal subject</measure>
    <time_frame>From baseline to Day 15 (+2 days)</time_frame>
    <description>Measured by using the equipment used at site for general practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure of the infant(s)</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Measured by using the equipment used at site for general practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate of the infant(s)</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Measured by using the equipment used at site for general practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical examination findings of the maternal subject</measure>
    <time_frame>From baseline to Day 15 (+2 days)</time_frame>
    <description>Change in physical examination measured at baseline and at day 15 evaluating general appearance, central and peripheral nervous system, head and neck, cardiovascular system, respiratory system, gastrointestinal system, lymphatic system, urinary system, breasts, skin, and musculoskeletal system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical examination findings of the infant(s)</measure>
    <time_frame>From baseline to Day 18</time_frame>
    <description>Change is recorded from the routine physical examination and collected from the hospital medical records, as available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (AEs) in maternal subjects</measure>
    <time_frame>Up to Day 15 (+2 days)</time_frame>
    <description>Measured from signing of informed consent to day 15/end-of-treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (AEs) in infants</measure>
    <time_frame>Until all milk has been consumed or discarded (an expected average of 6 weeks)</time_frame>
    <description>AEs of the infant will be collected from signing of parental informed consent until the infant is discharged from NICU or the last milk sample expressed during treatment iwth IMP is either consumed by the infant(s) or discarded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events (AEs) in maternal subjects</measure>
    <time_frame>Up to Day 15 (+2 days)</time_frame>
    <description>AEs will be categorised as mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events (AEs) in infants</measure>
    <time_frame>Until all milk has been consumed or discarded (an expected average of 6 weeks)</time_frame>
    <description>AEs will be categorised as mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in routine safety laboratory parameters in the maternal subject</measure>
    <time_frame>From baseline to Day 10 (+2 days)</time_frame>
    <description>The investigator will review the laboratory results and evaluate whether the results are clinically significant or not clinically significant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in routine safety laboratory parameters in the maternal subject</measure>
    <time_frame>From baseline to Day 15 (+2 days)</time_frame>
    <description>The investigator will review the laboratory results and evaluate whether the results are clinically significant or not clinically significant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Preterm Delivery</condition>
  <arm_group>
    <arm_group_label>Merotocin (a selective oxytocin-receptor agonist)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>merotocin</intervention_name>
    <description>Merotocin nasal spray</description>
    <arm_group_label>Merotocin (a selective oxytocin-receptor agonist)</arm_group_label>
    <other_name>FE 202767</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The placebo nasal spray is identical with the active product except that it does not contain merotocin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provided informed consent for the maternal subject and parental consent for the
             infant(s), prior to any trial activity

          -  Is a maternal subject aged 18 to 44 years

          -  Delivered at the hospital associated with the trial centre

          -  Had at least 1 and no more than 2 live-born infants from the current delivery

          -  Delivered preterm at gestational week 24/0 to 31/6

          -  Attempted initial milk expression within 12 hours of delivery

          -  Is willing to express milk 6 to 8 times daily, including at least once during the
             night and with no more than 5 hours between milk expression sessions, for up to 23
             days during observation, treatment, and follow-up periods

          -  After the first 24 hours following delivery, attempted milk expression at least 3
             times every 24 hours at each consecutive 24-hour interval

          -  Is willing to refrain from sexual intercourse during the trial

          -  Has been instructed to express milk 6 to 8 times daily, including at least once during
             the night and with no more than 5 hours between milk expression sessions

          -  Attempted milk expression using the breast pump at least 5 times every 24 hours during
             the observation period; note that subjects who entered the observation period soon
             after delivery will not be excluded if they pumped less frequently in the first 48
             hours after delivery, as long as they have met inclusion criteria 6 and 8

          -  Accurately recorded timing of milk expression after providing informed consent

          -  Produced &lt;200 mL milk at the 24-hour baseline interval towards the end of the
             observation period, i.e. within 24 hours prior to the last milk expression session
             using the breast pump before randomisation

          -  Delivered 96 to 144 hours prior to randomisation

        Exclusion Criteria:

          -  Has morbidity (chronic or temporary) or other condition or situation that would cause
             her to be unable to comply with the protocol or be unable to attend all trial visits

          -  Has mastitis

          -  Had known breast trauma, previous breast surgery (including breast augmentation or
             breast reduction) or nipple piercing

          -  Has known prolactin-releasing pituitary tumour, a history of Sheehan's syndrome, or
             had previous pituitary surgery or radiation therapy

          -  Has any known maternally driven contraindication to breast-feeding

          -  Has severe cardiovascular disease (e.g., uncontrolled hypertension, severe
             arrhythmias, or Grade 3-4 New York Heart Association cardiac failure)

          -  Has pre-pregnancy insulin-dependent diabetes mellitus, polycystic ovarian syndrome, or
             any other condition that would impact lactation in the opinion of the investigator

          -  Has unstable thyroid disease, i.e., has required dose adjustment of thyroid
             replacement or anti-thyroid medication in the 12 months prior to delivery

          -  Has known moderate or severe renal or hepatic impairment

          -  Has used or is currently using any of the following concomitant medications:

               -  Atypical anti-psychotic drugs during the previous 12 months (e.g., aripiprazole
                  [Abilify®], asenapine maleate [Saphris®], clozapine [Clozaril®], iloperidone
                  [Fanapt®], lurasidone [Latuda®], olanzapine [Zyprexa®], olanzapine/fluoxetine
                  [Symbyax®], paliperidone [Invega®], quetiapine [Seroquel®], and risperidone
                  [Risperdal®])

               -  Any non-registered investigational drugs from 90 days prior to delivery or within
                  5 half-lives of the drugs, whichever is longer

               -  Any hormonal contraception at any point following delivery

               -  Any pharmacologic or complementary (e.g., herbal) galactagogue therapy at any
                  point following delivery, including but not limited to oxytocin, prolactin,
                  metoclopramide, domperidone, sulpiride, fenugreek, shatavari, torbangun, milk
                  thistle

               -  Any concomitant medication that could impact lactation (e.g., medications with an
                  anti-dopamine effect, such as phenothiazine and haloperidol; other neuroleptics,
                  such as sulpiride and risperidone; the high blood pressure medication
                  α-methyldopa; and medications used to stimulate intestinal peristalsis,
                  domperidone, and metoclopramide) at any point following delivery

               -  Current use of oral steroids at any dose or inhaled steroids at doses &gt;600 µg/day

          -  Had postpartum haemorrhage of &gt;1500 mL

          -  Has used or is currently using any of the following concomitant medications:

               -  Prostaglandins at any point after providing informed consent

               -  Any current intra-nasally administered concomitant medications

               -  Methergine from 12 hours prior to randomisation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Development Support</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inadequate milk production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

